Cancer drug dosing study could mean fewer hospital visits

NCT ID NCT04295863

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 29 times

Summary

This study looks at whether two common immunotherapy drugs, nivolumab and pembrolizumab, can be given less frequently than the current standard schedule. Researchers will measure drug levels in the blood of 264 adults with advanced or metastatic cancer to see if extended intervals still keep drug concentrations high enough. The goal is to reduce the number of treatments needed without compromising effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • SSM Health Cancer Care

    RECRUITING

    Madison, Wisconsin, 53717, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Of Chicago Medicine Comprehensive Cancer Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.